Point of Care Testing of Inflammatory Markers in Tears

Status Completed

Clinical Trial Summary

To evaluate the use of a point of care device to measure markers of inflammation in various eye conditions. In particular, matrix metalloproteinase-9 (MMP-9) will be measured. MMP-9 is an enzyme that plays a role in inflammation. The value obtained with the point of care device will be correlated with values obtained using gel electrophoresis to measure MMP-9 from the same sample. These data will be compared to clinical exam findings and questionnaires to help the investigators better understand the role of this marker of inflammation in eye diseases and possibly improve diagnostic abilities.

Clinical Trial Description

As a participant in the study a sample of tears will be collected in a non-invasive manner by sitting comfortably at the slit lamp (a slit lamp is the standard device used to examine the eye and merely requires the participant to sit upright and place their chin on a chin rest and their forehead up against the slit lamp apparatus). The participant will then be asked to look upwards and while gently lowering the lower eyelid, a sterile blunt glass pipette will be used to collect tears from the natural tear lake (the tear lake is a reservoir of tears that sits on the surface of the eye and above the lower eyelid). Collected tears will then be taken for analysis of inflammatory markers.

In addition, a survey to evaluate the symptoms and the symptoms impact daily life (Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02315079
Study type	Observational
Source	University of Florida
Contact
Status	Completed
Phase
Start date	January 2015
Completion date	January 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02522312` - A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients	N/A
Completed	`NCT02597803` - Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1	Phase 2/Phase 3
Completed	`NCT01863368` - Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining	N/A
Completed	`NCT01753752` - Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation	Phase 2
Completed	`NCT01753687` - Correlation of Different Signs for Assessment of Dry Eye Syndrome	N/A
Completed	`NCT01212471` - A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease	Phase 3
Completed	`NCT01198782` - Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%	Phase 4
Completed	`NCT01162954` - Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers	Phase 1
Completed	`NCT00535054` - Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms	N/A
Completed	`NCT00544713` - Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery	N/A
Completed	`NCT00344721` - A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome	N/A
Completed	`NCT03830359` - Efficacy, Safety of T2769 in Dry Eye Disease	N/A
Completed	`NCT04139122` - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease	Phase 1/Phase 2
Completed	`NCT02758327` - Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops	Phase 4
Completed	`NCT01970917` - Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects	Phase 4
Completed	`NCT02066051` - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD	N/A
Completed	`NCT02092207` - Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome	Phase 2
Completed	`NCT01541891` - Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome	Phase 2
Completed	`NCT01252121` - Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline	N/A
Completed	`NCT00765804` - Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye	Phase 2